Cited by CrossRef (7)

  1. Yujin Shin, Haeri Choi, Soo Lim. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study. Diabetes Research and Clinical Practice 2021;175:108843
  2. Luke V. Selby, Aslam Ejaz, Stacy A. Brethauer, Timothy M. Pawlik. Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery. Expert Opinion on Investigational Drugs 2020;29:107
  3. Hoda Taheri, Mojtaba Malek, Faramarz Ismail-Beigi, Farhad Zamani, Masoudreza Sohrabi, Mohammad Reza babaei, Mohammad E. Khamseh. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther 2020;37:4697
  4. Juan Zheng, Ting Chen, Xin Guo, James M. Ntambi, Chaodong Wu. Lipid Signaling and Metabolism. 2020.
  5. Pieter Gillard, Oliver Schnell, Per-Henrik Groop. The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes. Diabetes Research and Clinical Practice 2020;170:108462
  6. Ronald M. Goldenberg, Vineeta Ahooja, Kristin K. Clemens, Jeremy D. Gilbert, Megha Poddar, Subodh Verma. Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. Canadian Journal of Diabetes 2021;45:291
  7. Rosemarie Lajara. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgraduate Medicine 2019;131:555